Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT03197792 Recruiting - Clinical trials for Pulmonary Hypertension

Perioperative Portal Vein Pulsatility as a Postoperative Prognostic Indicator in Pulmonary Endarterectomy

PVP-ETO-CPC
Start date: May 26, 2017
Phase: N/A
Study type: Interventional

The investigators aim to evaluate the utility of portal vein pulsatility as a predictor of the composite outcome of persistent organ dysfunction plus death in patients undergoing elective or urgent pulmonary endarterectomy for thromboembolic pulmonary hypertension. The investigators' hypothesis is that the portal vein pulsatility fraction, measured using transesophageal echocardiography immediately after weaning of cardiopulmonary bypass, is proportional to the risk of developing subsequent end-organ dysfunction in the postoperative setting.

NCT ID: NCT03197350 Recruiting - Clinical trials for Fibrosis Estimated by cMR Ant Biomarkers

Characterization of Heart Failure With Preserved Ejection Fraction

Start date: January 2015
Phase: N/A
Study type: Interventional

The goals of this research will be to define some of the mechanisms underlying the progression and complications of heart failure (HF) with preserved left ventricular ejection fraction (HFPEF) Aim 1: to evaluate the differences in cardiac structure, function and fibrosis markers through the spectrum of HF stages in order to deepen the understanding of the pathophysiology driving HF progression. Aim 2: to define the mechanisms by which HF risk factors, such as hypertension, diabetes, obesity, and renal insufficiency, interact with age to increase HF risk, and to evaluate the role of precipitating factors such as myocardial ischemia, atrial fibrillation in HFPEF. Aim 3: to determine prognostic factors in HFPEF patients, by following these patients over time. Accordingly the investigators will correlate baseline data (echocardiographic, MRI or biomarkers) with incident cardiovascular events and determine whether these measures provide incremental prognostic information beyond clinical characteristics.

NCT ID: NCT03195660 Not yet recruiting - Sleep Apnea Clinical Trials

Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study

CAT-PEF
Start date: June 2017
Phase: N/A
Study type: Interventional

This study is designed to demonstrate feasibility of study conduct and that acceptable adherence to adaptive servo-ventilation (ASV) therapy can be achieved in recently hospitalized HFpEF patients with moderate to severe sleep apnea. All subjects meeting the criteria will receive ASV therapy.

NCT ID: NCT03194841 Completed - Heart Failure Clinical Trials

Heart Failure Self-care With the Aid of a Smartphone Application

HFSC
Start date: August 22, 2016
Phase: N/A
Study type: Interventional

The purpose of this study was the development, and testing of a HF application that was used to provide self-care support to HF patients through a smartphone device. The study appraised current available literature on HF to determine best practices for promoting self-care of HF through direct communication with individuals with HF living at home. For the purpose of this study, smart phone communication was utilized. Smart phone applications allow patients to transmit physiological data, such as weight, blood pressure, heart rate, and symptom data to healthcare providers. Using a secure website, a healthcare worker can access the information and contact the patient via the mobile phone when their data is out of normal range. This study was novel in its approach from what is traditionally offered in that it supported patient self-care decisions by promoting symptom monitoring and offered both tactical and situational skills strategies through at the point education.

NCT ID: NCT03193801 Not yet recruiting - Heart Failure Clinical Trials

PARTNER 3 Trial - Mitral Valve in Valve

Start date: August 2017
Phase: N/A
Study type: Interventional

To assess the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve in patients with a failing mitral bioprosthetic valve.

NCT ID: NCT03191656 Not yet recruiting - Heart Failure Clinical Trials

REDUCE LAP-HF III Corvia Protocol 1701

REDUCELAPHFIII
Start date: July 4, 2017
Phase: N/A
Study type: Observational

This is a post market trial to be conducted at several sites in Germany. The device has CE approval in the EU. The purpose of this observational registry is to collect post market data in consecutive patients treated with the IASD System II, to further evaluate efficacy, safety and quality of life outcomes as a new treatment for patients with heart failure in a "real world" practice setting.

NCT ID: NCT03190304 Recruiting - Heart Failure Clinical Trials

The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure

NEPRIExTol
Start date: June 14, 2017
Phase: Phase 4
Study type: Interventional

Studies with new drugs in the treatment of heart failure (HF), such as the combination of valsartan/sacubitril, also known as LCZ696, have demonstrated important clinical impact on the morbidity and mortality outcomes in HF population. However, the effect of LCZ696 on the pathophysiological mechanisms of HF such as exercise tolerance (peak VO2) and peripheral muscle blood flow is not known. Since LCZ696 is a new drug with promising effects on the treatment of HF, the objective of the present study will be to evaluate the effect of LCZ696 in patients with HF on: 1) peak VO2, 2) 6-minute walk test, 3) peripheral muscle blood flow, 4) muscle strength, and 5) body composition.

NCT ID: NCT03189901 Not yet recruiting - Acute Heart Failure Clinical Trials

Early Management Strategies of Acute Heart Failure for Patients With NSTEMI

EMSAHF
Start date: July 1, 2017
Phase: Phase 4
Study type: Interventional

There are always poor outcomes in patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level. An elevated BNP/NT-proBNP level highly indicates acute heart failure(AHF).Levosimendan is recommended in many clinical trials of heart failure and Chinese heart failure guidelines. As a result, the investigators form a hypothesis that when patients with AMI combined with elevated BNP/NT-proBNP level are in conditions before AHF, to use levosimendan may reduces the risk of heart failure and improve the outcome.

NCT ID: NCT03189654 Not yet recruiting - Heart Failure Clinical Trials

Noninvasive Ventilation Therapy for the Treatment of Pleural Effusion in Patients With Heart Failure

Start date: June 2017
Phase: N/A
Study type: Observational [Patient Registry]

There are no investigations so far whether an application of positive pressure during non-invasive ventilation might be a therapeutic option for transudative pleural effusion in patients with heart failure. In view of the pathophysiological process with pleural effusion resulting from an increase in intravascular hydrostatic pressure, non-invasive ventilation might provide an improvement. The aim of the present study is to investigate whether an additional non-invasive ventilation therapy leads to an improved suppression of pleural effusion in heart failure patients.

NCT ID: NCT03189368 Not yet recruiting - Heart Failure Clinical Trials

Heart Failure Study of Multi-site Pacing Effects on Ventriculoarterial Coupling

HUMVEE
Start date: July 1, 2017
Phase: N/A
Study type: Observational

To perform a comparative study of multi-site left ventricular pacing and cardiac resynchronization therapy effects on ventriculoarterial coupling and energy efficiency of the failing heart